Company news
Noxopharm Ltd. news in 2026
Noxopharm Ltd.'s news releases, calls and decks from 2026, newest first.
Noxopharm Investor Webinar
November 5, 2026
Cleansing Statement
November 4, 2026
Application for quotation of securities - NOX
November 4, 2026
Proposed issue of securities - NOX
November 2, 2026
Proposed issue of securities - NOX
November 1, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
November 1, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
November 1, 2026
Proposed issue of securities - NOX
November 1, 2026
Proposed issue of securities - NOX
November 1, 2026
Reinstatement to Quotation
November 1, 2026
Reinstatement to Quotation
November 1, 2026
Noxopharm Successfully Raises $1.5 Million via Placement
November 1, 2026
Noxopharm Successfully Raises $1.5 Million via Placement
November 1, 2026
Voluntary Suspension
October 28, 2026
Trading Halt
October 26, 2026
2026 AGM Letter of Access, Notice of Meeting and Proxy
October 15, 2026
Appendix 4G and Corporate Governance Statement
October 15, 2026
Annual Report to shareholders
October 15, 2026
FDA feedback supports SOF-SKN Phase II plans
October 7, 2026
Audited Financial Statements
September 30, 2026
SOF-SKN to progress to extension study in CLE patients
September 13, 2026
Investor Presentation September 2026
September 3, 2026
Novel oligonucleotides data presented at Options Conference
August 31, 2026
Appendix 4E - Preliminary Financial Report
August 28, 2026
New preclinical data supports immuno-oncology approach
August 25, 2026
New study further validates Noxopharms cancer pipeline
August 3, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
July 21, 2026
SOF-SKN manufacturing begins to ensure clinical trial readi
June 8, 2026
New data confirms cancer-fighting potential
May 25, 2026
Noxopharms Sofra assets to be presented at global conference
May 19, 2026
Noxopharm progresses US regulatory strategy
May 5, 2026
New data shows SOF-SKN active ingredient efficacy
April 30, 2026
Innovative collaboration further expands Sofra platform
April 26, 2026
March 2026 Quarterly Activities Report and Appendix 4C
April 23, 2026
Positive SOF-SKN dosing data shows prolonged skin retention
April 21, 2026
Noxopharm appoints Dr Olivier Laczka as new CEO
April 14, 2026
Resignation of Chief Executive Officer
April 14, 2026
Appendix 4D and FY2026 Half Year Financial Report
February 27, 2026
R&D rebate strengthens cash position
February 26, 2026
At-the-Market (ATM) agreement with Acuity Capital
February 26, 2026
Sofra breakthrough science publish in major medical journal
February 10, 2026
December 2025 Quarterly Activities Report and Appendix 4C
January 29, 2026
HERACLES clinical trial successfully completed
January 20, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 23 slides · Sep 4, 2026